Successful ruxolitinib administration for a patient with steroid-refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review.

Dan TomomasaTakeshi IsodaNoriko MitsuikiMotoi YamashitaAoi MorishitaTakahiro TomodaTsubasa OkanoAkifumi EndoTakahiro KamiyaMasakatsu YanagimachiKohsuke ImaiHirokazu KaneganeMasatoshi TakagiTomohiro Morio

Published in: Clinical case reports (2021)

Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT-related IPS.

Keyphrases

stem cell transplantation
case report
respiratory failure
hematopoietic stem cell
high dose
drug induced
early onset
liver failure
acute myeloid leukemia
intensive care unit
decision making
hepatitis b virus